<DOC>
	<DOCNO>NCT00842660</DOCNO>
	<brief_summary>Concurrent radiotherapy cisplatin-based chemotherapy become standard treatment patient cervical cancer . However , patient advance cervical cancer , half treat contemporary radiotherapy plus single agent cisplatin still suffer local distant relapse . How improve treatment outcome patient important issue require clinical investigation . The major aim project conduct prospective , randomized phase III clinical trial examine cervical cancer patient treat radiotherapy cisplatin gemcitabine well survival rate treat radiotherapy cisplatin alone . Gemcitabine demonstrate good radiosensitizer . In keep , clinical trial early phase show promising result use concurrent radiotherapy cisplatin gemcitabine . According positive result , investigator expect trial potential improve survival patient advanced cervical cancer , reduce medical cost due tumor relapse , benefit whole society .</brief_summary>
	<brief_title>Radiotherapy With Single-Agent Cisplatin Combination Chemotherapy Defined Poor-Prognostic Cervical Cancer</brief_title>
	<detailed_description>I ) . Study end point Primary end point : Patient survival , include overall survival progression-free survival . Secondary end point : 1 . Acute toxicity treatment 2 . Tumor response rate 3 . Sites recurrence 4 . Long-term complication quality life II ) . Design study An open-label , prospective randomize trial two treatment arm : - Arm I : Patients receive CCRT weekly cisplatin . - Arm II : Patients receive CCRT cisplatin plus gemcitabine . III ) . Study population 1 ) Number subject : A total 172 patient ( 86 per treatment arm ) accrue study within 4 year . Conduct study</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically confirm primary squamous cell carcinoma uterine cervix . Previously untreated disease . Clinical FIGO stage IIIIVa pelvic/paraaortic lymph node positive PET examination . No known metastasis supraclavicular node organ outside radiotherapy field . Ages eligible : 35 year 70 year . Patients must adequate bone marrow , pulmonary , liver renal function document radiotherapy . WBC &gt; 3000/mm3 , platelet &gt; 100,000/mm3 , serum transaminase ( GOT , GPT ) &lt; 60 IU/ml , total bilirubin &lt; 1.5mg % , creatinine &lt; 1.4mg % ( creatinine clearance &gt; 60 ml/min ) . Performance status 0 1 ( see Appendix I ) . The interval RT randomization great 3 week . Patients must sign informed consent participate study . Age &gt; 70 &lt; 35 Medical psychological condition would preclude treatment . Previous chemotherapy pelvic RT . Small cell carcinoma , adenocarcinoma adenosquamous carcinoma . Patient unreliable treatment completion followup .</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Cervical cancer</keyword>
	<keyword>concurrent chemoradiotherapy</keyword>
	<keyword>gemcitabine</keyword>
</DOC>